(CercleFinance.com) – TME Pharma will seek the agreement of its shareholders to reduce the nominal value of its share and increase its authorized share capital, the biotechnology company announced on Friday.
The company has planned to convene an extraordinary general meeting for this purpose on January 30 at the offices of the law firm Freshfields Bruckhaus Deringer in Amsterdam.
The TME share, which was worth 2,200 dollars when it was listed on the stock exchange in 2016, is trading today around 1.4 euros following a consolidation of shares finalized last summer.
In late morning trading on the Paris Bourse, the title of the specialist in new therapies aimed at treating the most aggressive cancers rose by more than 18%.